<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337791</url>
  </required_header>
  <id_info>
    <org_study_id>H200804IRB</org_study_id>
    <nct_id>NCT01337791</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Telbivudine reduces DNA and normalizes alanine aminotransferase levels (ALT) in chronic
      hepatitis B patients with few adverse effects, but its use during pregnancy has not been
      explored. In this open-label, prospective study from the second trimester to post-partum week
      28. This trial is to study the efficacy, safety and tolerability of Telbivudine in HBeAg
      Positive Chronic Hepatitis B Pregnant Women with high level of serum HBV DNA and elevated
      alanine aminotransferase levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of Telbivudine treatment (DNA reduction, ALT normalization, and infants' immunoprophylaxis failure) and safety</measure>
    <time_frame>From late pregnancy to 28 weeks of postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in maternal HBeAg titers and lost/seroconversion of HBeAg or HBsAg</measure>
    <time_frame>From late pregnancy to 28 weeks of postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <condition>Pregnancy Complications</condition>
  <condition>High Viral Load</condition>
  <condition>Elevated Alanine Aminotransferase Levels</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>telbivudine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine treatment</intervention_name>
    <description>Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 20-40 years

          -  gestational age between 12-30 weeks

          -  serum HBsAg and HBeAg positivity

          -  HBV DNA levels &gt;6log10 copies/mL

          -  ALT &gt;1x ULN (40 IU/mL) and &lt; 10x ULN.

        Exclusion Criteria:

          -  co-infection with hepatitis A, C, D, E or HIV

          -  evidence of hepatocellular carcinoma; decompensated liver disease or significant
             renal, cardiovascular, respiratory or neurological co-morbidity

          -  concurrent treatment with immune-modulators, cytotoxic drugs, or steroids

          -  clinical signs of threatened miscarriage in early pregnancy

          -  evidence of fetal deformity by 3-dimensional ultrasound examination

          -  the biological father of the child had CHB
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics, The Second Affiliated Hospital of the Southeast University</name>
      <address>
        <city>Nan Jing</city>
        <state>Jiang Su</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Guo-Rong Han</name_title>
    <organization>The Second Affiliated Hospital of the Southeast University</organization>
  </responsible_party>
  <keyword>chronic hepatitis B</keyword>
  <keyword>hepatitis B virus</keyword>
  <keyword>perinatal transmission</keyword>
  <keyword>Telbivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

